Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene

Oncotarget

Volumn 4, Issue 4, 2013, Pages 584-599

  Hall, Arnaldur ^a,b   Meyle, Kathrine Damm ^c   Lange, Marina Krarup ^a   Klima, Martin ^a   Sanderhoff, May ^d   Dahl, Christina ^a   Abildgaard, Cecilie ^a   Thorup, Katrine ^a   Moghimi, Seyed Moein ^b   Jensen, Per Bo ^d   Bartek, Jiri ^a   Guldberg, Per ^a   Christensen, Claus ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c The Capital Region   (Denmark)

^d Seahorse Bioscience   (Denmark)

Author keywords

Glycolysis Oxidative phosphorylation; Melanoma; Oncogene addiction; The Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE;

ARTICLE; BRAF GENE; CELL METABOLISM; CONTROLLED STUDY; GLYCOLYSIS; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRION; ONCOGENE; ONCOGENE ADDICTION; ONCOLOGICAL PARAMETERS; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; SENESCENCE;

EID: 84879187712     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.965     Document Type: Article

References (61)

1. I.B. Weinstein, Cancer: Addiction to oncogenes - The Achilles heal of cancer, Science 297 (2002) pp. 63-64.
2. T. Holien, T.K. Vatsveen, H. Hella, A. Waage, A. Sundan, Addiction to c-MYC in multiple myeloma, Blood 120 (2012) pp. 2450-2453.
3. C.M. Shachaf, A.M. Kopelman, C. Arvanitis, A. Karlsson, S. Beer, S. Mandl, M.H. Bachmann, A.D. Borowsky, B. Ruebner, R.D. Cardiff, Q.W. Yang, J.M. Bishop, C.H. Contag, D.W. Felsher, MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer, Nature 431 (2004) pp. 1112-1117.
4. M. Jain, C. Arvanitis, K. Chu, W. Dewey, E. Leonhardt, M. Trinh, C.D. Sundberg, J.M. Bishop, D.W. Felsher, Sustained loss of a neoplastic phenotype by brief inactivation of MYC, Science 297 (2002) pp. 102-104.
5. D.W. Felsher and J.M. Bishop, Reversible tumorigenesis by MYC in hematopoietic lineages, Mol. Cell 4 (1999) pp. 199-207.
6. L. Chin, A. Tam, J. Pomerantz, M. Wong, J. Holash, N. Bardeesy, Q. Shen, R. O'Hagan, J. Pantginis, H. Zhou, J.W. Horner, C. Cordon-Cardo, G.D. Yancopoulos, R.A. DePinho, Essential role for oncogenic Ras in tumour maintenance, Nature 400 (1999) pp. 468-472.
7. C.S. Huettner, P. Zhang, R.A. Van Etten, D.G. Tenen, Reversibility of acute B-cell leukaemia induced by BCRABL1, Nat. Genet. 24 (2000) pp. 57-60.
8. J. Luo, N.L. Solimini, S.J. Elledge, Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (vol 136, pg 823, 2009), Cell 138 (2009) p.807.
9. L.F. Chang and M. Karin, Mammalian MAP kinase signalling cascades, Nature 410 (2001) pp. 37-40.
10. J. Downward, Targeting ras signalling pathways in cancer therapy, Nat. Rev. Cancer 3 (2003) pp. 11-22.
11. C. Michaloglou, L.C. Vredeveld, W.J. Mooi, D.S. Peeper, BRAF(E600) in benign and malignant human tumours, Oncogene 27 (2008) pp. 877-895.
12. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, N. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, et al., Mutations of the BRAF gene in human cancer, Nature 417 (2002) pp. 949-954.
13. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, R. Marais, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell 116 (2004) pp. 855-867.
14. C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-Duvaz, C.J. Springer, R. Marais, B-V599E-RAF is an oncogene in melanocytes, Cancer Res. 64 (2004) pp. 2338-2342.
15. M. Karasarides, A. Chiloeches, R. Hayward, D. Niculescu-Duvaz, I. Scanlon, F. Friedlos, L. Ogilvie, D. Hedley, J. Martin, C.J. Marshall, C.J. Springer, R. Marais, B-RAF is a therapeutic target in melanoma, Oncogene 23 (2004) pp. 6292-6298.
16. H. Sumimoto, M. Miyagishi, H. Miyoshi, S. Yamagata, A. Shimizu, K. Taira, Y. Kawakami, Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference, Oncogene 23 (2004) pp. 6031-6039.
17. C. Christensen and P. Guldberg, Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF, Oncogene 24 (2005) pp. 6292-6302.
18. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N.K. Haass, K. Sproesser, L. Li, K.S.M. Smalley, D. Fong, Y.L. Zhu, A. Marimuthu, et al., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) pp. 3041-3046.
19. E. Sala, L. Mologni, S. Truffa, C. Gaetano, G.E. Bollag, C. Gambacorti-Passerini, BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells, Mol. Cancer Res. 6 (2008) pp. 751-759.
20. H. Yang, RG7204 (PLX4032), a Selective BRAF(V600E) Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models (vol 70, pg 5518, 2010), Cancer Res. 70 (2010) p.9527.
21. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, N. Engl. J. Med. 364 (2011) pp. 2507-2516.
22. E.A. Collisson, A. De, H. Suzuki, S.S. Gambhir, M.S. Kolodney, Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade, Cancer Res. 63 (2003) pp. 5669-5673.
23. X.D. Zhang, J.M. Borrow, X.Y. Zhang, T. Nguyen, P. Hersey, Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/ DIABLO release from mitochondria, Oncogene 22 (2003) pp. 2869-2881.
24. B.R. Davies, A. Logie, J.S. Mckay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, P.D. Smith, AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models, Mol. Cancer Ther. 6 (2007) pp. 2209-2219.
25. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J.M. Lobo, Y.H. She, I. Osman, T.R. Golub, J. Sebolt-Leopold, W.R. Sellers, N. Rosen, BRAF mutation predicts sensitivity to MEK inhibition, Nature 439 (2006) pp. 358-362.
26. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, L.V. Demidov, J.C. Hassel, P. Rutkowski, P. Mohr, R. Dummer, U. Trefzer, J.M.G. Larkin, J. Utikal, B. Dreno, M. Nyakas, et al., Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma, N. Engl. J. Med. 367 (2012) pp. 107-114.
27. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, J.Y. Du, A. Davis, M.M. Mongare, J. Gould, D.T. Frederick, Z.A. Cooper, P.B. Chapman, D.B. Solit, A. Ribas, R.S. Lo, K.T. Flaherty, S. Ogino, J.A. Wargo, T.R. Golub, Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature 487 (2012) p.500-U118.
28. T.R. Wilson, J. Fridlyand, Y.B. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y.L. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D.P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growthfactor-driven resistance to anticancer kinase inhibitors, Nature 487 (2012) p.505-U1652.
29. M.G.V. Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation, Science 324 (2009) pp. 1029-1033.
30. P. Jiang, W.J. Du, X.W. Wang, A. Mancuso, X.A. Gao, M.A. Wu, X.L. Yang, p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase, Nat. Cell Biol. 13 (2011) p.310-U278.
31. P.S. Ward and C.B. Thompson, Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate, Cancer Cell 21 (2012) pp. 297-308.
32. R.A. Cairns, I.S. Harris, T.W. Mak, Regulation of cancer cell metabolism, Nat. Rev. Cancer 11 (2011) pp. 85-95.
33. O. Warburg, Origin of Cancer Cells, Science 123 (1956) pp. 309-314.
34. H.Q. Ying, A.C. Kimmelman, C.A. Lyssiotis, S.J. Hua, G.C. Chu, E. Fletcher-Sananikone, J.W. Locasale, J. Son, H.L. Zhang, J.L. Coloff, H.Y. Yan, W. Wang, S.J. Chen, A. Viale, H.W. Zheng, J.H. Paik, et al., Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism, Cell 149 (2012) pp. 656-670.
35. J.Y. Yun, C. Rago, I. Cheong, R. Pagliarini, P. Angenendt, H. Rajagopalan, K. Schmidt, J.K.V. Willson, S. Markowitz, S.B. Zhou, L.A. Diaz, V.E. Velculescu, C. Lengauer, K.W. Kinzler, B. Vogelstein, N. Papadopoulos, Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells, Science 325 (2009) pp. 1555-1559.
36. E. Yeh, M. Cunningham, H. Arnold, D. Chasse, T. Monteith, G. Ivaldi, W.C. Hahn, P.T. Stukenberg, S. Shenolikar, T. Uchida, C.M. Counter, J.R. Nevins, A.R. Means, R. Sears, A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells, Nat. Cell Biol. 6 (2004) pp. 308-318.
37. S.M. Kumar, H. Yu, R. Edwards, L.J. Chen, S. Kazianis, P. Brafford, G. Acs, M. Herlyn, X.W. Xu, Mutant V600E BRAF increases hypoxia inducible factor-1 alpha expression in melanoma, Cancer Res. 67 (2007) pp. 3177-3184.
38. N.T. Vu, Z.T.F. Yu, B. Comin-Anduix, J.N. Sondergaard, R.W. Silverman, C.Y.N. Chang, A. Ribas, H.R. Tseng, A.F. Chatziioannou, A beta-Camera Integrated with a Microfluidic Chip for Radioassays Based on Real-Time Imaging of Glycolysis in Small Cell Populations, J Nucl Med 52 (2011) pp. 815-821.
39. M.H. Lee, S.E. Lee, D.W. Kim, M.J. Ryu, S.J. Kim, S.J. Kim, Y.K. Kim, J.H. Park, G.R. Kweon, J.M. Kim, J.U. Lee, V. De Falco, Y.S. Jo, M. Shong, Mitochondrial Localization and Regulation of BRAF(V600E) in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAF(V600E), J. Clin. Endocrinol. Metab. 96 (2011) p.E19-E30.
40. M.D. Brand and D.G. Nicholls, Assessing mitochondrial dysfunction in cells, Biochem. J. 435 (2011) pp. 297-312.
41. D. Pesta and E. Gnaiger, High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle, Methods Mol. Biol. 810 (2012) pp. 25-58.
42. B. Zheng, J.H. Jeong, J.M. Asara, Y.Y. Yuan, S.R. Granters, L. Chin, L.C. Cantley, Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation, Mol. Cell 33 (2009) pp. 237-247.
43. J. Bartkova, J. Lukas, P. Guldberg, J. Alsner, A.F. Kirkin, J. Zeuthen, J. Bartek, The p16-cyclin D Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis, Cancer Res. 56 (1996) pp. 5475-5483.
44. H. Tsao, E. Benoit, A.J. Sober, C. Thiele, F.G. Haluska, Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene, Cancer Res. 58 (1998) pp. 109-113.
45. G. Jonsson, C. Dahl, J. Staaf, T. Sandberg, P.O. Bendahl, M. Ringner, P. Guldberg, A. Borg, Genomic profiling of malignant melanoma using tiling-resolution arrayCGH, Oncogene 26 (2007) pp. 4738-4748.
46. J.D. Berry and G.J.R. Cook, Positron emission tomography in oncology, British Medical Bulletin 79-80 (2006) pp. 171-186.
47. D.A. Scott, A.D. Richardson, F.V. Filipp, C.A. Knutzen, G.G. Chiang, Z.A. Ronai, A.L. Osterman, J.W. Smith, Comparative Metabolic Flux Profiling of Melanoma Cell Lines BEYOND THE WARBURG EFFECT, J. Biol. Chem. 286 (2011) pp. 42626-42634.
48. C.V. Dang, MYC on the Path to Cancer, Cell 149 (2012) pp. 22-35.
49. V. Gogvadze, B. Zhivotovsky, S. Orrenius, The Warburg effect and mitochondrial stability in cancer cells, Molecular Aspects of Medicine 31 (2010) pp. 60-74.
50. C.J. Ricketts, B. Shuch, C.D. Vocke, A.R. Metwalli, G. Bratslavsky, L. Middelton, Y.F. Yang, M.H. Wei, S.E. Pautler, J. Peterson, C.A. Stolle, B. Zbar, M.J. Merino, L.S. Schmidt, P.A. Pinto, R. Srinivasan, et al., Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer, Journal of Urology 188 (2012) pp. 2063-2071.
51. A.J. Gill, Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia, Pathology 44 (2012) pp. 285-292.
52. K.E. Yen, M.A. Bittinger, S.M. Su, V.R. Fantin, Cancerassociated IDH mutations: biomarker and therapeutic opportunities, Oncogene 29 (2010) pp. 6409-6417.
53. P. Vaupel and A. Mayer, Availability, not respiratory capacity governs oxygen consumption of solid tumors, Int. J. Biochem. Cell Biol. 44 (2012) pp. 1477-1481.
54. R. Rossignol, R. Gilkerson, R. Aggeler, K. Yamagata, S.J. Remington, R.A. Capaldi, Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells, Cancer Res. 64 (2004) pp. 985-993.
55. C. Frezza and E. Gottlieb, Mitochondria in cancer: Not just innocent bystanders, Seminars in Cancer Biology 19 (2009) pp. 4-11.
56. M. Wu, A. Neilson, A.L. Swift, R. Moran, J. Tamagnine, D. Parslow, S. Armistead, K. Lemire, J. Orrell, J. Teich, S. Chomicz, D.A. Ferrick, Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells, Am. J. Physiol. - Cell Physiol. 292 (2007) p.C125-C136.
57. K. Smolkova, L. Plecita-Hlavata, N. Bellance, G. Benard, R. Rossignol, P. Jezek, Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells, Int. J. Biochem. Cell Biol. 43 (2011) pp. 950-968.
58. A. Le, A.N. Lane, M. Hamaker, S. Bose, A. Gouw, J. Barbi, T. Tsukamoto, C.J. Rojas, B.S. Slusher, H.X. Zhang, L.J. Zimmerman, D.C. Liebler, R.J.C. Slebos, P.K. Lorkiewicz, R.M. Higashi, T.W.M. Fan, C.V. Dang, Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells, Cell Metab. 15 (2012) pp. 110-121.
59. Y. Shao and A.E. Aplin, BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma, Cell Death Differ. 19 (2012) pp. 2029-2039.
60. C. Munoz-Pinedo, C. Ruiz-Ruiz, C.R. De Almodovar, C. Palacios, A. Lopez-Rivas, Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing, J. Biol. Chem. 278 (2003) pp. 12759-12768.
61. A. Colell, D.R. Green, J.E. Ricci, Novel roles for GAPDH in cell death and carcinogenesis, Cell Death Differ. 16 (2009) pp. 1573-1581.